Jamjoom Pharmaceuticals Factory Valuation
Is 4015 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4015 (SAR140) is trading above our estimate of fair value (SAR114.08)
Significantly Below Fair Value: 4015 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4015?
Other financial metrics that can be useful for relative valuation.
| What is 4015's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ر.س9.80b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.6x |
| Enterprise Value/EBITDA | 27.8x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does 4015's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.1x | ||
4016 Middle East Pharmaceutical Industries | 45.5x | n/a | ر.س3.0b |
CORT Corcept Therapeutics | 24x | 26.4% | US$2.8b |
000739 Apeloa PharmaceuticalLtd | 17.3x | 18.1% | CN¥18.3b |
300558 Betta Pharmaceuticals | 45.4x | 21.1% | CN¥17.9b |
4015 Jamjoom Pharmaceuticals Factory | 33.5x | 14.5% | ر.س9.8b |
Price-To-Earnings vs Peers: 4015 is expensive based on its Price-To-Earnings Ratio (33.5x) compared to the peer average (33x).
Price to Earnings Ratio vs Industry
How does 4015's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4015 is expensive based on its Price-To-Earnings Ratio (33.5x) compared to the Asian Pharmaceuticals industry average (26.1x).
Price to Earnings Ratio vs Fair Ratio
What is 4015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 33.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4015's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س140.00 | ر.س142.10 +1.5% | 1.1% | ر.س143.31 | ر.س140.00 | n/a | 3 |
| May ’25 | ر.س133.00 | ر.س142.10 +6.8% | 1.1% | ر.س143.31 | ر.س140.00 | n/a | 3 |
| Apr ’25 | ر.س128.80 | ر.س132.10 +2.6% | 7.2% | ر.س143.31 | ر.س120.00 | n/a | 3 |
| Mar ’25 | ر.س144.40 | ر.س118.28 -18.1% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Feb ’25 | ر.س138.60 | ر.س118.28 -14.7% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Jan ’25 | ر.س114.60 | ر.س118.28 +3.2% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Dec ’24 | ر.س114.00 | ر.س118.28 +3.8% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Nov ’24 | ر.س108.40 | ر.س115.28 +6.3% | 11.8% | ر.س134.00 | ر.س101.85 | n/a | 3 |
| Oct ’24 | ر.س118.40 | ر.س115.28 -2.6% | 11.8% | ر.س134.00 | ر.س101.85 | n/a | 3 |
| Sep ’24 | ر.س116.20 | ر.س122.00 +5.0% | 9.8% | ر.س134.00 | ر.س110.00 | n/a | 2 |
| Aug ’24 | ر.س120.80 | ر.س122.00 +1.0% | 9.8% | ر.س134.00 | ر.س110.00 | n/a | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.